Liraglutide Injection
Product Images NDC 50090-7501

Product Visual Gallery

This gallery contains 34 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 50090-7501). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-1 (Figure 1)

Chemical structure diagram of liraglutide showing its amino acid sequence in a ribbon-like arrangement. Key residues such as Glu linked to a C-16 fatty acid (palmitoyl) and Arg with Lys are highlighted, illustrating the molecular components of liraglutide.*

FDA Label Image

Figure-2 (Figure 2)

A line graph comparing ISR (pmol/kg/min) versus Plasma Glucose (mg/dL) for Liraglutide and Placebo groups. Liraglutide is represented by black diamonds, showing higher ISR values across plasma glucose levels from 90 to 220 mg/dL compared to the Placebo group, represented by gray triangles.*

FDA Label Image

Figure_3 (Figure 3)

A line graph showing mean HbA1c percentage over 52 weeks for three treatments: Glimepiride, Liraglutide 1.2 mg, and Liraglutide 1.8 mg. The x-axis represents time in weeks, and the y-axis represents mean HbA1c percentage. The graph depicts a decrease in HbA1c levels initially, followed by varying trends among the treatments over time.*

FDA Label Image

Figure_4 (Figure 4)

A line graph comparing mean HbA1c (%) levels over time (weeks) among patients treated with Liraglutide 1.2 mg, Liraglutide 1.8 mg, and Sitagliptin 100 mg. The graph shows mean HbA1c decreasing from about 8.5% at week 0 to lower levels at week 12 for both liraglutide doses, with relatively stable trends through week 26. Sitagliptin shows a smaller reduction in HbA1c levels maintained from week 12 to week 26.*

FDA Label Image

Figure-5 (Figure 5)

A Kaplan-Meier curve comparing the percentage of patients with an event over time (in months) between Liraglutide and placebo groups. The graph displays patient counts at risk over 54 months and includes a hazard ratio (HR) of 0.87 with a 95% confidence interval (CI) of 0.78 to 0.97. Liraglutide shows lower event rates compared to placebo throughout the study period.*

FDA Label Image

Pen_image (Image 01)

Liraglutide 6 mg/mL injection in a single-dose pen injector. The pen is blue with a label indicating liraglutide injection and a warning for single-patient use. It is a subcutaneous injection device provided by A-S Medication Solutions.*

FDA Label Image

Injection-pen (Image 22)

Illustration of the Liraglutide Injection Pen, subcutaneous injection device for 6 mg/mL liraglutide. The diagram labels key parts including the pen cap, rubber stopper, cartridge tip, cartridge, cartridge scale, dose display, pointer, dose button, dose selector, and flow check symbol, explaining components of the injection pen.*

FDA Label Image

Needle-example (Image 23)

An instructional diagram labeled 'Needle (example)' showing four separate components of an injection needle: the outer needle cap, inner needle cap, needle, and protective tab. Each component is illustrated and labeled with blue text, depicting the parts of a needle assembly for subcutaneous injection.*

FDA Label Image

Triangle_1 (Image 24)

Liraglutide 6 mg/mL injection label from A-S Medication Solutions. The label features dosing and usage instructions for subcutaneous administration, along with information on ingredients, storage, and handling. The label is white with black text and includes warning and caution statements relevant to pharmaceutical use.*

FDA Label Image

Triangle_2 (Image 25)

Liraglutide injection 6 mg/mL in a single-dose pen device, labeled for subcutaneous use. The pen is primarily white with a blue cap and is branded by A-S Medication Solutions. The label features the proprietary name Liraglutide prominently along with the concentration and dosage form.*

FDA Label Image

Triangle_3 (Image 26)

Liraglutide 6 mg/mL injection single-dose cartridge carton, labeled for subcutaneous use. The packaging shows a white box with a green gradient and geometric design. It includes the proprietary name Liraglutide, dosage strength 6 mg/mL, and indicates a 3 mL cartridge containing 18 mg total. The labeler is A-S Medication Solutions.*

FDA Label Image

Tirangle_4 (Image 27)

Liraglutide 6 mg/mL injection in a 3 mL single-dose glass cartridge with gray rubber stopper and gray plastic cap holder. The cartridge has printed text markings and scale graduations visible on the glass. The labeler is A-S Medication Solutions.*

FDA Label Image

Triangle_5 (Image 28)

FDA Label Image

Triangle_6 (Image 29)

FDA Label Image

Tirangle_7 (Image 30)

Liraglutide injection 6 mg/mL single-dose vial packaging label by A-S Medication Solutions. The label highlights the generic name liraglutide, concentration 6 mg/mL, and injection route subcutaneous. The vial's NDC is 50090-7501, indicating a prescription human drug in injectable form.*

FDA Label Image

Triangle_8 (Image 31)

Liraglutide 6 mg/mL injection vial label by A-S Medication Solutions. The label includes drug name, strength, dosage form (subcutaneous injection), and other regulatory text and markings consistent with prescription medication vials.*

FDA Label Image

Image-a (Image 32)

An instructional illustration showing hands manipulating a liraglutide injection device, depicting a step where a part of the device is being pulled or pushed, indicated by a blue arrow pointing outward.*

FDA Label Image

Image-b (Image 33)

An instructional illustration labeled 'B' showing a person holding a prefilled syringe for subcutaneous injection, with an arrow indicating the cap is being removed by pulling it upward.*

FDA Label Image

Image-c (Image 34)

Instructional illustration showing a hand holding a pen-style injection device, with the thumb pushing forward on the injection button indicated by a blue arrow, demonstrating the injection process for a subcutaneous liraglutide injection.*

FDA Label Image

Image-d (Image 35)

An instructional illustration showing a hand inserting or attaching a small cap or cover onto the tip of an injection pen device. An arrow indicates the direction of placement. The image likely pertains to the preparation or use of the liraglutide injection pen.*

FDA Label Image

Image-e (Image 36)

An instructional diagram showing a person holding a liraglutide injection pen with an arrow indicating rotation of the dose selector. The illustration highlights the selection of the flow check symbol on the injection device.*

FDA Label Image

Image-f (Image 37)

An instructional illustration showing a close-up of a hand holding a vial or syringe for subcutaneous injection, indicating a shaking or mixing motion prior to use.*

FDA Label Image

Image-g (Image 38)

Illustration showing a hand holding a liraglutide injection pen with the dose selector knob being twisted upward. An inset shows a close-up of the pen tip, and another inset displays the dose window set to zero milligrams, indicating dose adjustment.*

FDA Label Image

Image-h (Image 39)

Illustration showing a close-up of a hand holding a blue injection device, with an arrow indicating a sliding or pushing motion of a part of the device. The image suggests a step in the preparation or administration of a subcutaneous injection.*

FDA Label Image

Image-i (Image 40)

An instructional illustration showing a hand holding a subcutaneous injection pen for liraglutide. The image depicts the thumb lifting a protective cap or cover from the pen, indicated by an arrow pointing upward, as the first step in preparing the injection.*

FDA Label Image

Image-j (Image 41)

An instructional illustration showing a hand gripping the cap of a prefilled injection pen for subcutaneous use, with an arrow indicating the direction to remove the cap, part of the usage process for a liraglutide injection pen.*

FDA Label Image

Image-k (Image 42)

An instructional illustration showing a hand removing a protective cap from the tip of a pen injector, indicating preparation of the injection device prior to use.*

FDA Label Image

Image-l (Image 43)

An instructional illustration showing how to adjust the dose on a liraglutide injection pen by rotating the dose selector. The image displays dose options of 0.6 mg, 1.2 mg, and 1.8 mg selected on the dose dial.*

FDA Label Image

Image-m (Image 44)

An instructional illustration showing a hand pressing down on the top of a dosage pen, likely for liraglutide injection, with a close-up inset displaying a dose indicator set to 0 mg.*

FDA Label Image

Image-n (Image 45)

An instructional illustration showing a hand holding a pen-style injection device vertically against the skin for subcutaneous administration. A downward arrow indicates the direction of injection. A stopwatch icon with the number 6 suggests holding the injection in place for 6 seconds.*

FDA Label Image

Image-o (Image 46)

An instructional illustration showing a subcutaneous injection technique with an upward arrow indicating the direction to insert or lift the injection device away after administration, emphasizing proper needle placement under the skin.*

FDA Label Image

Image-p (Image 47)

An illustration showing the process of removing a protective cap from a syringe needle. The image depicts a syringe with measurement markings, pointing toward a circular protective cap with an arrow indicating the cap should be pulled off to expose the needle.*

FDA Label Image

Image-q (Image 48)

An instructional illustration showing a close-up of hands manipulating a liraglutide injection pen. One hand holds the injector pen steady while the other hand positions the thumb to press or activate the injection mechanism, indicated by a blue arrow pointing towards the pen tip.*

FDA Label Image

Label Image (Lbl500907501)

Liraglutide 6 mg/mL injection label from A-S Medication Solutions. The label includes dosing information indicating each pen contains 18 mg per 3 mL, with a total of 3 pens per package. Storage instructions specify refrigeration without freezing. The label also shows the NDC 50090-7501 and QR code for dosage instructions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.